Journal of Pharmacy and Pharmacology最新文献

{"title":"Correction to: Modulation of NADPH oxidase and Nrf2/HO-1 pathway by vanillin in cisplatin-induced nephrotoxicity in rats.","authors":"","doi":"10.1093/jpp/rgaf057","DOIUrl":"10.1093/jpp/rgaf057","url":null,"abstract":"","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":"1459"},"PeriodicalIF":3.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated progression of honokiol in lung cancer treatment.","authors":"Ziwei Gao, Yuping Yang, Na Huang, Wei Zhao","doi":"10.1093/jpp/rgaf007","DOIUrl":"10.1093/jpp/rgaf007","url":null,"abstract":"<p><strong>Objectives: </strong>Despite significant advancements in innovative therapy, lung cancer continues to have an unexpectedly low 5-year survival rate. This necessitates the urgent development of novel and effective therapies. One such potential therapy is Honokiol (HNK, C18H18O2), a biphenolic natural compound isolated from the leaves and bark of Magnolia plant species. The objective of this review is to examine the various studies supporting the anti-lung cancer effects of HNK and its potential use in the treatment of lung cancer.</p><p><strong>Key findings: </strong>Emerging research has shown that HNK possesses a range of pharmacological characteristics that make it a promising agent in the fight against lung cancer. Specifically, HNK has been found to regulate various molecular targets, including the activation of pro-apoptotic factors and the suppression of anti-apoptotic proteins and different transcription factors. It also downregulates various enzymes, chemokines, cell surface adhesion molecules, and cell cycle proteins. Additionally, HNK inhibits the activity of protein tyrosine kinases and serine/threonine kinases. These effects contribute to its ability to efficiently prevent the progression of lung cancer, either solely or in combination with other therapeutic strategies. Furthermore, several nanotechnologies have been employed to modify HNK for the treatment of lung cancer, enhancing its potential efficacy.</p><p><strong>Summary: </strong>In summary, Honokiol (HNK) is a biphenolic natural compound with significant anti-lung cancer properties. Its pharmacological characteristics, including the regulation of various molecular targets and the inhibition of key enzymes and kinases, make it a promising agent for the treatment of lung cancer. Emerging research supports its ability to prevent the progression of lung cancer, either alone or in combination with other therapies. Additionally, nanotechnologies have been used to modify HNK, potentially enhancing its efficacy in the treatment of lung cancer. This review highlights the various studies documenting the anti-lung cancer effects of HNK, underscoring its potential as a novel and effective therapy for this deadly disease.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":"1293-1302"},"PeriodicalIF":3.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143784415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting together cholinesterases and serotonin reuptake against Alzheimer's disease.","authors":"Thomas Guiselin, Cédric Lecoutey, Christophe Rochais, Patrick Dallemagne","doi":"10.1093/jpp/rgaf041","DOIUrl":"10.1093/jpp/rgaf041","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline and memory loss, with limited therapeutic options. Traditional treatments primarily focus on acetylcholinesterase inhibitors (AChEIs), which aim to increase acetylcholine levels in the brain, and selective serotonin reuptake inhibitors (SSRIs), which modulate serotonin levels. However, these treatments often provide only modest symptom relief. This review explores the potential benefits of combined targeting of cholinesterases and serotonin reuptake as a novel therapeutic strategy for AD. We discuss the pathophysiological role of acetylcholine and serotonin in AD, highlighting their impact on cognitive function, mood regulation, and neuroplasticity. By targeting both cholinergic and serotonergic systems, this dual approach may offer synergistic effects, improving cognitive function, reducing neuropsychiatric symptoms, and enhancing neuroprotective mechanisms. The review also examines preclinical and clinical studies investigating the efficacy of combination therapies and outlines the challenges and opportunities in their development. Ultimately, this combined targeting approach holds promise for providing more effective and comprehensive treatment options for AD, addressing both cognitive and behavioural symptoms associated with the disease.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":"1303-1318"},"PeriodicalIF":3.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective role of geraniol in high fat diet-induced NAFLD: balancing lipid homeostasis, antioxidant defence, and inflammatory responses.","authors":"Sakeena Noor, Fakhria A Al-Joufi, Ambreen Malik Uttra, Sumera Qasim, Aiman Afzal","doi":"10.1093/jpp/rgaf053","DOIUrl":"10.1093/jpp/rgaf053","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate the preventive effects of geraniol on non-alcoholic fatty liver disease (NAFLD) induced by a high fat diet (HFD) in a rat model, focusing on its impact on lipid metabolism, oxidative stress, and inflammation.</p><p><strong>Methods: </strong>NAFLD was induced in male Sprague-Dawley rats by feeding them a HFD for 10 weeks. Geraniol was administered orally at doses of 50, 100, and 200 mg/kg. The following parameters were assessed: body weight, hepatic index, lipid profile (total cholesterol, triglycerides, HDL, LDL), serum hepatic enzymes (ALT, AST, ALP), oxidative stress markers (MDA, SOD, CAT, GSH), and inflammatory markers (TNF-α, IL-6, IL-10). Histopathological evaluation of liver tissues was performed to assess structural changes and inflammation.</p><p><strong>Key findings: </strong>Geraniol treatment, particularly at 100 and 200 mg/kg, significantly reduced body weight gain and hepatic index in HFD-fed rats. It improved lipid profiles by lowering total cholesterol, triglycerides, and LDL while increasing HDL levels. Hepatic enzyme levels were markedly decreased, indicating hepatoprotection. Geraniol also restored antioxidant enzyme activity and reduced markers of oxidative stress. Moreover, it lowered pro-inflammatory cytokines and elevated anti-inflammatory cytokines. Histopathological analysis confirmed reduced hepatic steatosis and inflammation.</p><p><strong>Conclusions: </strong>Geraniol demonstrated potent protective effects against HFD-induced NAFLD in rats by improving lipid metabolism, mitigating oxidative stress, and modulating inflammatory responses. These findings support its potential as a therapeutic agent for the prevention and management of NAFLD.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":"1439-1449"},"PeriodicalIF":3.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Key signalling pathways in head and neck squamous cell carcinoma: mechanisms and therapeutic targets.","authors":"Enas Bani-Ahmad, Joshua Dass, Crispin R Dass","doi":"10.1093/jpp/rgaf093","DOIUrl":"https://doi.org/10.1093/jpp/rgaf093","url":null,"abstract":"<p><strong>Objectives: </strong>This review examines the signalling pathways involved in head and neck cancer cell survival and apoptosis.</p><p><strong>Methods: </strong>Articles were sourced from Scopus using the following keywords: oral cavity cancer, head and neck squamous cell carcinoma, signalling pathways, target therapy. No publication date limits were set, and the language of publication was restricted to English.</p><p><strong>Key findings: </strong>Head and neck cancers are the sixth most common cancer worldwide (head and neck squamous cell carcinoma [HNSCC]). The most common subtype is squamous cell carcinoma (SCC), with oral and oropharyngeal squamous cell carcinoma (OSCC and OPSCC, respectively) being significant subcategories. Multiple signalling pathways play a critical role in oncogenesis and the development of various head and neck malignancies. Theoretically, targeting inhibitors for these pathways could potentially halt tumour growth and restore affected cells. This review highlights key oncogenic cascades, including epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT/mTOR, mitogen-activated protein kinase/extracellular signal-regulated kinase, Wnt/β-catenin, NOTCH, the p53 gene, and vascular endothelial growth factor, which contribute to tumour progression, invasion, and therapeutic resistance. A comprehensive understanding of these molecular mechanisms is essential to inform targeted therapies and develop personalized treatment strategies for HNSCC.</p><p><strong>Conclusions: </strong>Researchers have studied several signalling pathways in HNSCC due to their known ability to influence apoptosis, survival, angiogenesis, and other biological processes.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and innovations in long-acting injectable formulations: can formulation design space be rationalized?","authors":"Andrew Otte, Kinam Park, Tonglei Li","doi":"10.1093/jpp/rgaf080","DOIUrl":"https://doi.org/10.1093/jpp/rgaf080","url":null,"abstract":"<p><strong>Objectives: </strong>To date, ~70 long-acting injectable (LAI) formulations have been developed. More than half of these formulations consist of oily solutions and suspensions containing poorly water-soluble drugs. However, numerous drugs do not fall into the category of poor solubility, such as hydrophilic small molecules, nucleic acids, peptides, and proteins. These drugs are typically formulated using biodegradable poly(lactide-co-glycolide) polymers. An important question to consider is whether there are guiding principles for selecting appropriate drugs for LAI formulations. The historical advancements and challenges associated with LAI formulations were examined to identify indicators that may predict effective drug candidates for this type of delivery system.</p><p><strong>Key findings: </strong>Several properties of drugs, including water solubility, lipophilicity, tissue permeability, half-life (t1/2), and effective dosage, were analysed in relation to the development of LAIs. This study investigated several parameters to forecast formulation success, with a focus on achieving an optimal balance between the drug's partition coefficient (logP), which reflects both water solubility and cellular permeability, and the effective dose.</p><p><strong>Summary: </strong>The current overview of recent innovations and formulation considerations indicates that a systematic approach, integrating two key parameters, logP and the effective dose of a drug, may be employed for the preliminary screening of drugs that have the potential to be formulated into LAIs with a higher probability of success in clinical applications.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additive cardioprotection by dapagliflozin and pioglitazone co-therapy in streptozotocin-induced diabetic rats.","authors":"Eva Kralova, Aneta Cinakova, Jan Klimas, Peter Krenek","doi":"10.1093/jpp/rgaf091","DOIUrl":"https://doi.org/10.1093/jpp/rgaf091","url":null,"abstract":"<p><strong>Objectives: </strong>In diabetes mellitus, inflammation and apoptosis contribute to cardiovascular injury and oxidative damage. Dapagliflozin and Pio, beyond their hypoglycemic effects, mitigate organ damage. This study explored whether their combination provides enhanced protection against cardiac damage in streptozotocin-induced diabetic rats.</p><p><strong>Methods: </strong>Wistar rats were divided into control, diabetic (STZ, 55 mg/kg, i.p.), dapagliflozin-treated (10 mg/kg, chow), pioglitazone-treated (12 mg/kg, chow), and combination groups. After six weeks, systolic blood pressure, glucose, and lipids were assessed; subsequently, the left ventricle was excised for real-time quantitative PCR and western blot analyses.</p><p><strong>Key findings: </strong>Both drugs alleviated STZ-induced weight loss, water intake, and urine output without significant glucose reduction. The monotherapy also effectively modulated oxidative stress, inflammation, and apoptosis. The combination of drugs led to a more favourable lipid profile than the individual drugs. Dapagliflozin + pioglitazone additively upregulated MnSOD, normalized Bcl2 and Bax/Bcl2 ratios, and decreased tumour necrosis factor-α levels in the left ventricle. These effects were associated with improved cardiac damage markers (Myh6/Myh7 ratio) and systolic blood pressure compared to the administration of the drugs alone.</p><p><strong>Conclusions: </strong>Combined dapagliflozin and pioglitazone protect diabetic rat hearts by reducing oxidative stress, inflammation, and apoptosis, independently of glycemic control. This combination therapy offers a promising approach to mitigate cardiovascular complications in diabetes.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oleanolic acid attenuates cardiac hypertrophy by improving endothelial mitochondrial function and inhibiting pyroptosis.","authors":"Xiaolei Li, Jing Wu, Bo Lin, Wenhui Zhao, Qiu Jin, Ting Lin, Zhonghua Li, Dandan Shao","doi":"10.1093/jpp/rgaf092","DOIUrl":"https://doi.org/10.1093/jpp/rgaf092","url":null,"abstract":"<p><strong>Purpose: </strong>Cardiac microvascular impairment serves a function in cardiac hypertrophy (CH). Oleanolic acid (OA), a bioactive pentacyclic triterpenoid substance, has been extensively investigated for its anti-inflammatory and antioxidant characteristics. This investigation sought to elucidate the involvement of pyroptosis and mitochondrial malfunction in microvascular damage and examine the potential of OA in inhibiting pyroptosis and mitigating endothelial injury.</p><p><strong>Methods: </strong>We utilized a rat CH model and performed several experiments, encompassing network pharmacology, molecular docking, western blot, morphological analysis, mitochondrial membrane potential detection, mitochondrial oxygen consumption rate assay and enzyme-linked immunosorbent assay kit detection.</p><p><strong>Results: </strong>Network pharmacology approaches were employed to forecast the potential molecular targets of OA. The results showed that OA interacts with signal transducer and activator of transcription 3 (STAT3), nuclear factor kappa-B (NF-κB), peroxisome proliferator-activated receptor gamma (PPARG), and Interleukin-1β (IL-1β). Echocardiography data showed that OA remarkably improves cardiac function, and inhibits CH in rats. Mechanistically, upregulation of p-STAT3 expression, NF-κB p65 and IL-1β, but downregulation of PPARG could be detected in the hearts of CH rat and in cardiac microvascular endothelial cells (CMECs) exposed to Ang II. In addition, OA decreased STAT3 and NF-κB phosphorylation and up-regulated PPARG, thereby inhibiting pyroptosis and improving mitochondrial function.</p><p><strong>Conclusion: </strong>OA rescued mitochondrial function and inhibited CMEC pyroptosis by directly interacting with PPARG, STAT3, NF-κB, and IL-1β, and then suppressed CH.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in ultrasound-mediated brain drug delivery.","authors":"Yinxu Wang, Qian Wen, Anli Hu, Xin Chen, Jingjing Liu, Jingyi Lin, Yulei Xie","doi":"10.1093/jpp/rgaf090","DOIUrl":"https://doi.org/10.1093/jpp/rgaf090","url":null,"abstract":"<p><strong>Objectives: </strong>The primary objective of this review is to summarize research cases and recent advances in ultrasound technology for overcoming the blood-brain barrier (BBB) and facilitating drug delivery to the brain, thereby providing insights to promote research on enhancing drug permeation across the BBB.</p><p><strong>Key findings: </strong>This review summarizes recent advances in focused ultrasound combined with microbubbles to enhance BBB permeability for brain-targeted drug delivery. It covers the mechanisms by which ultrasound and microbubbles open the BBB, the factors influencing this process, and their applications in brain diseases. Finally, existing challenges in the field are highlighted, and the prospects for clinical translation are discussed.</p><p><strong>Summary: </strong>Ultrasound combined with microbubble technology can safely, non-invasively, and reversibly open the BBB and deliver drugs, offering novel strategies and methods for the treatment of brain diseases.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145175988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cyclodextrin-based formulations for pediatric patients: pharmaceutical prospectives and toxicological evaluation.","authors":"Theingi Tun, Hay Marn Hnin, Vu Minh Triet, Thorsteinn Loftsson, Phatsawee Jansook","doi":"10.1093/jpp/rgaf088","DOIUrl":"https://doi.org/10.1093/jpp/rgaf088","url":null,"abstract":"<p><p>Pediatric drug development faces significant challenges due to age-specific physiological differences, with limited approved formulations often resulting in off-label or extemporaneous uses. Oral administration remains the most common route in children, with ideal formulations requiring dosing flexibility and palatability. Cyclodextrins (CDs) have emerged as effective excipients for pediatric applications due to their ability to enhance aqueous solubility, improve chemical stability, and mask unpleasant tastes. Despite their extensive use in adult formulations, their application in pediatric formulations remains limited. Pharmacokinetic studies in juvenile animals reveal age-dependent renal clearance of CDs, with neonates demonstrating delayed elimination. Clinical findings indicate that hydroxypropyl-β-cyclodextrin and sulfobutylether-β-cyclodextrin are generally well tolerated in pediatric populations; however, neonatal use requires caution due to potential accumulation related to immature renal function. Despite limited regulatory approval, CD-based systems have effectively improved pediatric formulations. Advances in pediatric-friendly dosage forms, such as orodisperable tablets, mucoadhesive films, and 3D-printed mini-tablets, have further highlighted the versatility of CDs. Nonetheless, comprehensive safety data and defined regulatory guidelines are essential for broader clinical application. This review outlines the role of CD complexation in pediatric drug delivery, summarizes the relevant pharmacokinetic and toxicity findings in children, and presents examples of CD-based pediatric formulations.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}